Azra AI, a Nashville company that automates follow-up of incidental imaging findings and cancer care workflows for health systems, announced on April 28, 2026 that it had acquired Thynk Health of Lexington, Kentucky. Financial terms were not disclosed.
Thynk makes software for lung cancer screening programmes and for managing incidental findings. Its technology will be folded into Azra's platform, and health systems that use Thynk will get access to Azra's full product. Azra's existing clients gain Thynk's lung cancer screening features.
John Marshall remains chief executive of the combined company. Daniel Weeks, Thynk's chief executive, becomes Azra's chief operating officer. Both companies said existing customer contracts and workflows would continue without disruption during the integration.
What Thynk Health built
Thynk focuses on the period between an imaging finding and a confirmed diagnosis, when a missed or delayed follow-up can allow a cancer to progress to a later stage. Its software is delivered as a service to lung cancer screening programmes, organising the data-driven workflows behind them and providing operational and clinical analytics for screening and other quality programmes.
Weeks said too many imaging findings never lead to action and that this was the problem Thynk was built to solve. He said joining Azra would give Thynk the reach to coordinate care across entire health system populations rather than single programmes.
“Too many important imaging findings never lead to action — a missed follow-up, a gap in communication, and a patient's early-stage diagnosis becomes a late-stage one.”
Why Azra is buying
Azra describes its core product as a Clinical Patient Data Layer that turns scattered clinical data into structured workflows across radiology, pathology, cardiology and emergency departments. Its platform covers incidental findings, identifying cancer patients from pathology reports, patient navigation and care coordination, cancer registry case-finding, tumour boards, clinical trial matching and reporting. It also offers hands-on services such as navigation, case finding and tumour board coordination.
Marshall said health systems were moving away from separate point tools toward enterprise-wide platforms, and that electronic health records were not built for the specialised workflows that turn a finding into a follow-up. He said the aim was to identify high-risk patients earlier, often before they have symptoms.
Azra says it uses agentic AI, multimodal data integration and workflow automation in products for lung and breast cancer screening, incidental findings, multidisciplinary meetings, care coordination, clinical trial matching and emergency department discharge. Before the deal it had announced partnerships with 4DMedical on lung health and with Blackford on connecting imaging AI to care coordination.
Scale of the combined company
The companies said the combined platforms were deployed in hundreds of hospitals, including five of the ten largest health systems in the United States, and together processed more than half a billion clinical reports and messages a year. They claimed the largest installed base in their market segment.
Neither company disclosed revenue, headcount or the number of hospitals each brought to the deal.
Weeks said Azra's clinical services, which include navigation, case finding, tumour board coordination and programme execution, give hospitals a partner that works alongside their staff rather than only a tool to operate themselves. He said no other product on the market combined these in one platform. The trade publication AuntMinnie reported the deal on May 1, again without financial details.
The funding behind both companies
Thynk Health announced in January 2019 that it had raised $2.2 million from private investors including the Bluegrass Angels, and that it had received a $250,000 jobs grant from the Lexington-Fayette Urban County Government. Jeffrey Markowitz was its chief executive at the time. No later funding was confirmed in the deal announcement.
Azra AI is a portfolio company of SJF Ventures, according to Preqin. In a separate story, AuntMinnie reported that Sopris Capital was buying Blackford Analysis from Bayer and planned to fold it into Azra, which it described as one of its portfolio companies.
